AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

Core Insights - AP Biosciences has initiated a Phase 1 clinical trial for AP402, a bispecific antibody targeting CD137 and p95HER2 in patients with advanced solid tumors who are relapsed/refractory to anti-HER2 treatment [1][2] - AP402 targets p95HER2, which is present in 30-40% of HER2-positive cancers and is associated with poor prognosis, offering a differentiated mechanism to enhance immune response while minimizing systemic toxicity [2][4] - The trial aims to enroll up to 85 patients and will assess safety, tolerability, and preliminary efficacy, with a focus on specific HER2-positive tumor types in subsequent phases [2][4] Company Overview - AP Biosciences is a Taiwan-based clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapies for cancer and other diseases [5] - The company utilizes proprietary platforms such as Omni-Mab and T-cube to create next-generation bispecific antibodies that activate the immune system precisely in the tumor microenvironment [5] Product Details - AP402 is designed to activate T-cells specifically in the tumor microenvironment, addressing treatment-resistant HER2-positive cancers [4] - The antibody employs T-cube bispecific technology to enhance the immune response while reducing potential side effects related to systemic cytokine release [4]